Your email has been successfully added to our mailing list.

×
0 -0.0112149532710281 -0.00981308411214957 -0.0080934579439253 -0.0080934579439253 -0.0080934579439253 -0.0080934579439253 -0.0080934579439253
Stock impact report

Erytech Pharma: Buy The Dip [Seeking Alpha]

Erytech Pharma S.A. - American Depositary Shares (ERYP) 
US:NASDAQ Investor Relations: investors.erytech.com
Company Research Source: Seeking Alpha
Erytech Pharma: Buy The DipSummaryThe stock has fallen by over 20% since my initial article in December.A ¨failed study¨ in AML appears to be a minor setback.I revisit the bullish thesis below and remind readers of two upside driveres, ALL and pancreatic cancer.A main point of differentiation for lead candidate eryaspase, namely its toxicity profile, remains intact.Readers who have done their due diligence should purchase a pilot position in the very near term and ¨buy the dips¨ adding periodically over a period of several months while closely monitoring technicals. Show less Read more
Impact Snapshot
Event Time:
ERYP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ERYP alerts
Opt-in for
ERYP alerts

from News Quantified
Opt-in for
ERYP alerts

from News Quantified